Chinese biomedical CRO seals $77m fundraising for R&D push
Animal gene modifier Beijing Biocytogen managed to draw on both government and private capital for its Series D funding round.
August 08, 2019
Over the past five years, biotech investment has experienced the fastest development in China. Pharmaceutical companies have become a rising force that has attracted increasing amount of capital.
¬ Haymarket Media Limited. All rights reserved.
